Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer-High Responder (MEGASET-HR) trial.
F S Rep
; 1(3): 257-263, 2020 Dec.
Article
in En
| MEDLINE
| ID: mdl-34223253
ABSTRACT
OBJECTIVE:
To determine the cost of achieving a live birth after first transfer using highly purified human menotropin (HP-hMG) or recombinant follicle-stimulating hormone (FSH) for controlled ovarian stimulation in predicted high-responder patients in the Menopur in Gonadotropin-releasing hormone Antagonist Single Embryo Transfer-High Responder (MEGASET-HR) trial.DESIGN:
Cost minimization analysis of trial results.SETTING:
Thirty-one fertility centers. PATIENTS Six hundred and nineteen women with serum antimüllerian hormone ≥5 ng/mL.INTERVENTIONS:
Controlled ovarian stimulation with HP-hMG or recombinant FSH in a gonadotropin-releasing hormone (GnRH) antagonist assisted reproduction cycle where fresh transfer of a single blastocyst was performed unless ovarian response was excessive whereupon all embryos were cryopreserved and patients could undergo subsequent frozen blastocyst transfer within 6 months of randomization. MAIN OUTCOMEMEASURES:
Mean cost of achieving live birth after first transfer (fresh or frozen).RESULTS:
First-transfer efficacy, defined as live birth after first fresh or frozen transfer, was 54.5% for HP-hMG and 48.0% for recombinant FSH (difference 6.5%). Average cost to achieve a live birth after first transfer (fresh or frozen) was lower with HP-hMG compared with recombinant FSH. For fresh transfers, the cost was lower with HP-hMG compared with recombinant FSH. The average cost to achieve a live birth after first frozen transfer was also lower in patients treated with HP-hMG compared with recombinant FSH.CONCLUSIONS:
Treatment of predicted high-responders with HP-hMG was associated with lower cost to achieve a live birth after first transfer compared with recombinant FSH. CLINICAL TRIAL REGISTRATION NUMBER NCT02554279.
Full text:
1
Database:
MEDLINE
Type of study:
Clinical_trials
/
Health_economic_evaluation
/
Prognostic_studies
Language:
En
Year:
2020
Type:
Article